Sue Anschutz-Rodgers Eye Center’s Post

🌟 Introducing the Marsden M-999 Patient Transfer Scale! 🌟 1. Revolutionary Weighing: Imagine weighing time-critical or immobile patients in seconds. No more uncertainty! The M-999 provides accurate readings without the guesswork. 2. Quick and Easy: Forget complicated setups. This scale is as simple as it gets. Just use it with a slide sheet during lateral transfer from trolley to bed. Voilà! Weight measured, confidence restored. ⚖️ 3. MUST Compliance: The M-999 isn’t just about numbers; it’s about compliance. 4. Clinical Versatility: Whether you’re in a hospital, clinic, or community setting, the M-999 shines. It’s designed for accuracy, portability, and ease of use. #weighingscale #health Ask MDI medical for more information.

My main takeaways from another amazing Dermsquared #FallClinical: 1) The dermatology pipeline is immense. Numerous novels MoAs are incoming for #HidradenitisSuppurativa #AtopicDermatitis and #ChronicSpontaneousUrticaria. While big Pharma including most notably Sanofi Eli Lilly and Company AbbVie Incyte Johnson & Johnson Novartis and Takeda have many Ph2-Ph3 assets, a plethora of smaller biotech interests including, but certainly not limited, to Alumis Apogee Therapeutics Oruka Therapeutics Q32 Bio Inc. Celldex Therapeutics MoonLake Immunotherapeutics (NASDAQ: MLTX) AnaptysBio are also involved. 2) "The Year of the JAK" Since it may be a while until many of the these assets can make it to the finish line, we need to utilize what we have available right now for our patients (which is still pretty good!). I heard Dr. Theodore Rosen call this the "The Year of the JAK" and I couldn't agree more. Janus kinase inhibitors are being used more and more as dermatology providers come to the realization that these therapies can be used with a high degree of safety with proper patient selection and counseling. As these therapies get approved for more conditions of unmet need (i.e. Rinvoq in #vitiligo and #alopeciaareata, povorcitinib in #HS), our patients will expect us to be competent in prescribing these oral small molecules. 3) We are so blessed to be in dermatology. Not just dermatologists, but all of us including our industry colleagues, advanced practice providers, biologics coordinators, medical assistants, front office staff, and everyone else... our patients for the most part are doing well and on good therapies, and I've developed so many friendships across the dermatology ecosystem for which I'm very grateful.

Advancing health care through state-of-the-art technology.

Treatment is a personal experience for each and every patient... shouldn't we treat it as such during clinical trial participation, too? In this video interview, Julia Lakeland discusses how new technologies can personalize the clinical trial experience for diverse patient populations. She emphasizes the need for inclusivity and equitable access to participation, considering factors like age, access to resources, and cultural needs. Ultimately, supporting patients' expectations and tailoring the technology to their needs is crucial in promoting diverse participation in clinical research.

In this Next Level interview with Jen Uschold, learn how a course or certification program focused on Lifestyle Medicine from Evidence In Motion (EIM) can help take your career and quality of patient care to the next level! 🚀

Why rubber backed vinyl? - Impact reduction - Comfort under foot - Acoustical value Hands down one of the best products for healthcare and assisted living projects. If safety, comfort, and sound reduction are key for a new project, why not go ahead and order some samples?

💫 Introducing our first Publication Review 📽️ This series highlights recent publications on #AI in radiology, its impact on patients and healthcare, and the Annalise.ai team’s commitment to improving lives through innovation. In this episode, Mark Phillips, Chief Clinical Officer at Annalise.ai, explores key insights from Professor Sir Gregor Smith, Chief Medical Officer, NHS Scotland's annual report. The report emphasises people, the planet, and progress toward delivering sustainable, patient-centred care. 📌 Annalise’s partnership with NHS Scotland reduced chest X-ray-to-CT times by 54%  📌 The proportion of patients with lung cancer who met the 62-day treatment target increased from 52% to 100%! Our AI is helping reduce radiologist burnout, improve diagnostic accuracy, and enable faster and smarter decision-making. By blending our comprehensive yet customisable technology with compassionate care, #Scotland is setting a global standard for the future of healthcare. Meet our clinical experts at the Radiological Society of North America (RSNA) conference in Chicago next week. https://lnkd.in/gEQ_Beny

Curious about the different investigative site models available today and their impact on sponsors’ site management and engagement strategies? The new Tufts Center for the Study of Drug Development (Tufts CSDD) working study, Assessing Sponsors' Site Utilization Strategies and Practices: Impact and Long-Term Viability in an Evolving Global Investigative Site Landscape, explores these questions and more. Connect with me to learn more about this exciting study.

Talking about a global approach to clinical trials & diversity together with Estelle Jobson at SCOPE! 🌞

Join us for the first part of our enlightening discussion with Dr. Norbert Gleicher and Dr. Zeev Shoham as they delve into the critical 'Window of Preimplantation.' 🧬 Don't miss out on this expert dialogue! Watch now and bring your questions! #FertilityInsights #IVF